- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Pharma Pulse 11/11/24: The Importance of Improving DE&I in Clinical Trials, Financial Toxicity About More Than Just Affording Treatment & more
The latest news for pharma industry insiders.
Peer Exchange: The Importance of Improving DE&I in Clinical Trials
In this roundtable discussion, industry experts gathered to address the state of achieving greater diversity in clinical research. The group highlighted a variety of topics including current challenges they are seeing, the use of technology, and more.
Moderated by Otis Johnson, PhD, MPA Co-Founder & Principal Consultant, Trial Equity, the panel featured key insights from Sophia McLeod, Sr. Director, Government Relations, ACRO; Erin Stern, PharmD, Research Support Pharmacist, Mayo Clinic; and Caitlin Brown, PharmD, Neurocritical Care and Emergency Medicine Clinical Pharmacist, Mayo Clinic.
Why Financial Toxicity is About More Than Just Affording Treatment
The idea of financial toxicity combines the physical stress of having a disease like breast cancer with concerns about affording treatment, according to Laila Gharzai, M.D., LLM, from the Department of Radiation Oncology at Northwestern University.
U.S. Agency Warns Employees About Phone Use Amid Ongoing China Hack
Consumer Financial Protection Bureau tells workers to reduce use of cellphones for work due to risk from China-linked telecom intrusion.
No-Cost Heart & Kidney Health Screening Available on Nov. 11-14 in Houston
Care Access is bringing its Heart & Kidney Health Screening initiative to Houston, Texas. This health screening aims to raise awareness and provide testing for certain health risk factors, including a dangerous type of cholesterol known as lipoprotein(a), or Lp(a), which impacts one in five people and significantly increases the risk of heart disease and stroke.
Check out this article from Pharmaceutical Executive. The global radiopharmaceutical market is on track to grow from $9.07 billion in 2023 to an impressive $26.51 billion by 2031, fueled by advancements in diagnostic and therapeutic applications for conditions like cancer and Alzheimer’s disease.
Established markets in North America continue to benefit from robust infrastructure and innovation in theranostics and AI-driven personalized medicine. This evolution is a game-changer in healthcare, promising enhanced treatment precision and expanded patient access worldwide.
Read the full article:https://bit.ly/3O14fcZ
#Radiopharmaceuticals #HealthcareInnovation #Theranostics
Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs
ROI and Rare Disease: Retooling the ‘Gene’ Value Machine
November 14th 2024Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
